Current Oncology
Risk Stratification and Factors Associated with Heart Failure Hospitalization During Osimertinib Therapy
Par Tomoya Sugimoto, Yoshinori Noguchi, Rikuto Masuda et 5 autres.
Contenu en anglais
Résumé
Background
Osimertinib is the standard of care for epidermal growth factor receptor mutation-positive non-small cell lung cancer, but heart failure hospitalization (HFH) remains a concern, and no practical tool exists to stratify HFH risk during therapy.
Methods
In this retrospective cohort study using a Japanese claims database, 5802 patients newly initiating osimertinib were followed for HFH during treatment. Baseline predictors assessed before the index date were selected by 10-fold cross-validated least absolute shrinkage and selection operator (LASSO) logistic regression and internally validated by bootstrapping (B = 500), repeating predictor selection in each resample. Cumulative incidence functions and Fine–Gray models treated death as a competing event; cause-specific Cox models served as sensitivity analyses.